Outlook Optim sales picked up sharply in the second half of the financial year. The additional functionality and improvements in the Optim2 product have been well received by the market and the Directors expect to see a good performance from this business unit in the coming financial year.
The Directors are naturally very pleased to see the shipping of the first Sensipod units to veterinary practices in the UK and recognise that the expansion of the menu of diagnostic tests over the coming months and years is critical to the growth of the installed base. This is a key area of focus for the Group. The animal health business unit now has three revenue streams from reference laboratory testing, diagnostic kit sales and Sensipod in-clinic testing and the Directors are confident that the pipeline of new products in each of these three areas will drive growth.
Progress in the two focus areas for Affimers, commercialisation as reagents for life sciences research and microarrays for drug and biomarker discovery, is good and the Group remains on target to generate first revenues in calendar 2014.
The Market Makers will only change the price of a share if they think that they can make money out of doing so. With Avacta, there have been very few trades and very little news to encourage trading so there would be no point in changing the sp. Mandatory trading? sorry, no idea.
I would be grateful from some advice from more experienced investors - I'm very much a novice! Regarding this share, what does a status of 'mandatory trading' mean on the London Stock Exchange website? Secondly, why does the price of this share change so little? E.g. on Google finance it hasn't updated since this morning. Is there a reason for that, beyond a technical fault with that site?
"Chablis"? Hmph - that's for communists! Burgundy is so passé. Now coal tar cordial is where it's at. More seriousl I cannot think of a semi-fledgling company trading on a public exchange today with more potential (commercial and - by virtue of the nature of their products - philanthropic) than AVCT. May be a bumpy ride, though, given cashflow requirements, but at least most of the R & D has been completed successfully.
Excellent post PP and that's what most reasonable people think in this country at the moment. Lemonaider you are also right in stating that Avacta has failed to make any money to date, but I have visited the company and met with Alastair Smith and believe me when I say that He is a seriously clever guy and a shrewd businessman and I still maintain that in 2014 you could easily double or triple your money, you just need a bit more patience. I've been here since 2009 and fully confident that I will be rewarded for sticking with Avacta.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.